Corvus Pharmaceuticals, Inc. Income (Loss) from Equity Method Investments
Corvus Pharmaceuticals, Inc. (CRVS) reported Income (Loss) from Equity Method Investments of -$709.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Other Income
us-gaap:IncomeLossFromEquityMethodInvestments · last filed 2026-08-06
- Corvus Pharmaceuticals, Inc. income (loss) from equity method investments for the quarter ending 2026-06-30 was -$709.00K.
- Corvus Pharmaceuticals, Inc. income (loss) from equity method investments for the quarter ending 2026-03-31 was -$599.00K.
- Corvus Pharmaceuticals, Inc. income (loss) from equity method investments for the quarter ending 2025-12-31 was -$707.00K.
- Corvus Pharmaceuticals, Inc. income (loss) from equity method investments for the quarter ending 2025-09-30 was -$323.00K.
- Corvus Pharmaceuticals, Inc. income (loss) from equity method investments for fiscal 2025 was -$1.96M.
- Corvus Pharmaceuticals, Inc. income (loss) from equity method investments for fiscal 2024 was -$3.20M.
- Corvus Pharmaceuticals, Inc. income (loss) from equity method investments for fiscal 2023 was -$5.28M.
- Corvus Pharmaceuticals, Inc. income (loss) from equity method investments for fiscal 2022 was -$10.01M.
| Period end | Income (Loss) from Equity Method Investments 3 month | Income (Loss) from Equity Method Investments 6 month | Income (Loss) from Equity Method Investments 9 month | Income (Loss) from Equity Method Investments 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$709.00K 10-Q · filed 2026-08-06 | -$1.31M 10-Q · filed 2026-08-06 | -$2.02M derived: sum of 3 quarters · filed 2026-08-06 | -$2.34M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$599.00K 10-Q · filed 2026-05-07 | -$1.31M derived: sum of 2 quarters · filed 2026-05-07 | -$1.63M derived: sum of 3 quarters · filed 2026-05-07 | -$2.02M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$707.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$1.03M derived: sum of 2 quarters · filed 2026-03-12 | -$1.42M derived: sum of 3 quarters · filed 2026-08-06 | -$1.96M 10-K · filed 2026-03-12 |
| 2025-09-30 | -$323.00K 10-Q · filed 2025-11-04 | -$712.00K derived: sum of 2 quarters · filed 2026-08-06 | -$1.25M 10-Q · filed 2025-11-04 | -$3.42M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$389.00K 10-Q · filed 2026-08-06 | -$928.00K 10-Q · filed 2026-08-06 | -$3.10M derived: sum of 3 quarters · filed 2026-08-06 | -$3.78M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$539.00K 10-Q · filed 2026-05-07 | -$2.71M derived: sum of 2 quarters · filed 2026-05-07 | -$3.40M derived: sum of 3 quarters · filed 2026-05-07 | -$3.97M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$2.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$2.86M derived: sum of 2 quarters · filed 2026-03-12 | -$3.43M derived: sum of 3 quarters · filed 2026-03-12 | -$3.20M 10-K · filed 2026-03-12 |
| 2024-09-30 | -$682.00K 10-Q · filed 2025-11-04 | -$1.26M derived: sum of 2 quarters · filed 2025-11-04 | -$1.02M 10-Q · filed 2025-11-04 | -$2.43M derived: sum of 4 quarters · filed 2026-03-12 |
| 2024-06-30 | -$577.00K 10-Q · filed 2025-08-07 | -$341.00K 10-Q · filed 2025-08-07 | -$1.75M derived: sum of 3 quarters · filed 2026-03-12 | -$2.61M derived: sum of 4 quarters · filed 2026-03-12 |
| 2024-03-31 | $236.00K 10-Q · filed 2025-05-08 | -$1.17M derived: sum of 2 quarters · filed 2026-03-12 | -$2.03M derived: sum of 3 quarters · filed 2026-03-12 | -$3.32M derived: sum of 4 quarters · filed 2026-03-12 |
| 2023-12-31 | -$1.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$2.27M derived: sum of 2 quarters · filed 2026-03-12 | -$3.55M derived: sum of 3 quarters · filed 2026-03-12 | -$5.28M 10-K · filed 2026-03-12 |
| 2023-09-30 | -$865.00K 10-Q · filed 2024-11-12 | -$2.15M derived: sum of 2 quarters · filed 2024-11-12 | -$3.88M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | -$1.28M 10-Q · filed 2024-08-06 | -$3.02M 10-Q · filed 2024-08-06 | ||
| 2022-12-31 | -$10.01M 10-K · filed 2025-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Apnimed, Inc. (APMD) | United States | $0.899B |